8-K
filed April 16, 2026, 7:59 PM ET
ticker ACHV
CIK 0000949858
other material
confidence high
sentiment positive
materiality 0.80
Achieve Life Sciences raises $180M in private placement (up to $354M with warrants); CEO replaced
ACHIEVE LIFE SCIENCES, INC.
- Gross proceeds of $180M upfront; warrants could add $174M if FDA approves cytisinicline for smoking cessation.
- CEO Richard Stewart steps down April 18; remains on board. New CEO Andrew Goldberg appointed.
- Board adds directors Lucian Iancovici and Aaron Royston; Frazier Life Sciences to designate a third.
- Proceeds to fund Phase 3 e-cigarette cessation trial and commercialization of cytisinicline.
- Warrants exercise price $3.51, expire 20 business days after FDA approval announcement.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001193125-26-159189
- form_type
- 8-K
- ticker
- ACHV
- cik
- 0000949858
- company_name
- ACHIEVE LIFE SCIENCES, INC.
- filed_at
- 2026-04-16T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:33.963833+00:00
- generated_at
- 2026-05-15T05:59:49.095547+00:00
- sec_items
- ["1.01", "3.02", "5.02", "7.01", "9.01"]
- event_type
- other_material
- sentiment
- positive
- materiality_score
- 0.8
- calibrated_materiality_score
- 0.8
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001193125-26-159189
- json_url
- https://secwatch.observer/filing/0001193125-26-159189.json
- markdown_url
- https://secwatch.observer/filing/0001193125-26-159189.md
- text_url
- https://secwatch.observer/filing/0001193125-26-159189.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/949858/000119312526159189/0001193125-26-159189-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/949858/000119312526159189/achv-20260415.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
DGAC
Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE
DISCIPLINED GROWTH ACQUISITION Corp
June 1, 2026, 4:15 PM ET
other_material
Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 5.02, 9.01
same event type: other_material
similar materiality
This filing
On April 15, 2026, Achieve Life Sciences, Inc. (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) an aggregate of (i) 49,418,069 shares (the “Shares”) of the Company’s common stock
Comparable filing
A Share Rights Agreement, dated May 26, 2026, by and between the Company and Odyssey Transfer and Trust Company, as rights agent
Filing page
SEC filing
SAGU
Shreya Acquisition Group closes $110M IPO, 11M units at $10 each on NYSE
Shreya Acquisition Group
May 11, 2026, 7:59 PM ET
other_material
Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 5.02, 9.01
same event type: other_material
similar materiality
This filing
On April 15, 2026, Achieve Life Sciences, Inc. (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) an aggregate of (i) 49,418,069 shares (the “Shares”) of the Company’s common stock
Comparable filing
Private Units Subscription Agreement, dated May 6, 2026, by and between the Company and the Sponsor, a copy of which is attached as Exhibit 10.4 and incorporated herein by reference
Filing page
SEC filing
SUJA
Suja Life completes IPO of 8.9M shares at $21/share; closes May 8, 2026
SUJA LIFE, INC.
May 8, 2026, 7:59 PM ET
other_material
Items 1.01, 3.02, 3.03, 5.03, 5.02, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 5.02, 9.01
same event type: other_material
similar materiality
This filing
On April 15, 2026, Achieve Life Sciences, Inc. (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) an aggregate of (i) 49,418,069 shares (the “Shares”) of the Company’s common stock
Comparable filing
On May 6, 2026, Suja Life, Inc. (the “Company”) and Suja Life Holdings, L.P. (“Holdings LP”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, Jefferies LLC, and William Blair & Company, L.L.C., as representatives of the several underwriters named therein (collectively, the “Underwriters”) relating to the initial public offering (the “IPO”) of the Company’s Class A common stock
Filing page
SEC filing
QMCO
Quantum raises $100M equity, converts all convertible notes to equity; Q4 revenue above guidance
QUANTUM CORP /DE/
June 2, 2026, 10:41 AM ET
other_material
Items 1.01, 2.02, 2.03, 3.02, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: other_material
similar materiality
This filing
On April 15, 2026, Achieve Life Sciences, Inc. (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) an aggregate of (i) 49,418,069 shares (the “Shares”) of the Company’s common stock
Comparable filing
In connection with the Private Placement, the Company entered into Registration Rights Agreements with the Investors, dated as of June 1, 2026 (the “PIPE Registration Rights Agreement”), pursuant to which the Company has agreed to (i) prepare and file a registration statement with the Securities and Exchange Commission (the “SEC”) covering the resale of the Common Stock sold in the Private Placement within 45 days of the closing of the Private Placement, (ii) use commercially reasonable efforts to have such registration statement declared effective within the time period set forth in the PIPE Registration Rights Agreement, and to keep such registration statement effective until the date that all registrable securities covered by such registration statement (a) have been sold, thereunder or pursuant to Rule 144, or (b) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for 1 the Company to be in compliance with the current public i
Filing page
SEC filing
USAR
USA Rare Earth selects South Carolina for $1.2B magnet facility; 490 jobs, 6,400 tpa capacity
USA Rare Earth, Inc.
June 2, 2026, 9:14 AM ET
other_material
Items 1.01, 2.03, 7.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 7.01, 9.01
same event type: other_material
similar materiality
This filing
On April 15, 2026, Achieve Life Sciences, Inc. (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) an aggregate of (i) 49,418,069 shares (the “Shares”) of the Company’s common stock
Comparable filing
On June 1, 2026, USA Rare Earth, Inc. (the “Company”) entered into a Lease Agreement (the “Lease”) with TC Liberty Development, LLC, a Delaware limited liability company (“Landlord”), for the lease of a to-be-constructed specialty rare earth magnet manufacturing facility located on Bear Den Road in Blacksburg, Cherokee County, South Carolina (the “Premises”).
Filing page
SEC filing
TPST
Tempest Therapeutics enters warrant exercise inducement for ~$2M; issues new warrants to purchase 2.34M shares at $1.73
Tempest Therapeutics, Inc.
June 1, 2026, 7:13 PM ET
other_material
Items 1.01, 3.02, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: other_material
similar materiality
This filing
On April 15, 2026, Achieve Life Sciences, Inc. (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) an aggregate of (i) 49,418,069 shares (the “Shares”) of the Company’s common stock
Comparable filing
On May 28, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a warrant exercise and inducement offer letter agreement (the “ Inducement Letter ”) with a holder of certain existing warrants to purchase shares of the Company’s common stock
Filing page
SEC filing
KRMN
Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds
Karman Holdings Inc.
June 1, 2026, 5:28 PM ET
other_material
Items 1.01, 7.01, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 7.01, 9.01
same event type: other_material
similar materiality
This filing
On April 15, 2026, Achieve Life Sciences, Inc. (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) an aggregate of (i) 49,418,069 shares (the “Shares”) of the Company’s common stock
Comparable filing
On May 28, 2026, Karman Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the persons named in Schedule II thereto (the “Selling Stockholders”) and Citigroup Global Markets Inc. and Evercore Group L.L.C., as the underwriters (the “Underwriters”), pursuant to which the Selling Stockholders agreed to sell 14,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a public offering price of $61.00 per share (the “Offering Price”), less underwriting discounts and commissions (the “Offering”).
Filing page
SEC filing
CLRB
Cellectar raises ~$35M via stock/warrant offering; reports positive 12-mo Phase 2b WM data
Cellectar Biosciences, Inc.
May 8, 2026, 7:59 PM ET
other_material
Items 1.01, 3.02, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: other_material
similar materiality
This filing
On April 15, 2026, Achieve Life Sciences, Inc. (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) an aggregate of (i) 49,418,069 shares (the “Shares”) of the Company’s common stock
Comparable filing
pursuant to an additional securities purchase agreement with certain members of the executive management team of the Company (the “Management Purchase Agreement”
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.